A large-scale clinical trial of nicotinamide mononucleotide (NMN) supplementation has demonstrated significant increases in NAD+ levels but produced inconsistent results across functional health measures, according to findings published in Nature Aging. The multi-center study tracked over 300 participants across 12 weeks of supplementation, marking one of the most comprehensive investigations to date of this popular anti-aging compound.
Researchers documented a 40-60% elevation in blood NAD+ concentrations among participants taking daily NMN doses ranging from 250mg to 1000mg, confirming the supplement’s ability to boost this critical cellular metabolite. However, the functional outcomes painted a more complex picture. While some biomarkers of metabolic health showed modest improvements—including a 5-7% reduction in insulin resistance among a subset of participants—measures of physical performance, cognitive function, and cardiovascular fitness remained largely unchanged from baseline.
The mixed results arrive amid explosive consumer interest in NAD+ boosters, with the global NMN supplement market projected to exceed $500 million annually. Proponents have promoted these compounds as potential interventions for age-related decline, based partly on promising animal studies showing benefits in mitochondrial function and cellular repair. This human trial suggests the translation from laboratory to clinic may be more nuanced than initially hoped.
Lead investigators noted significant variability in individual responses, with approximately 30% of participants showing meaningful improvements in secondary endpoints while others demonstrated no measurable benefit beyond NAD+ elevation itself. This heterogeneity suggests that baseline NAD+ status, genetic factors, or other individual characteristics may determine who benefits most from supplementation.
For consumers currently taking or considering NMN supplements, these findings emphasize the importance of realistic expectations. While the compound clearly enters circulation and raises NAD+ levels, this biochemical change doesn’t automatically translate to improved health outcomes for all users. Researchers are calling for longer-duration studies and better identification of responsive patient populations before NMN can be recommended as a standard anti-aging intervention.
